{"id":"td-4208","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL596854","moleculeType":"Small molecule","molecularWeight":"322.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Nav1.5, TD-4208 is thought to reduce the risk of atrial fibrillation and its associated complications. This mechanism of action is based on the channel's role in the regulation of cardiac electrical activity.","oneSentence":"TD-4208 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:36.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT02518139","phase":"PHASE3","title":"A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1060},{"nctId":"NCT02820311","phase":"PHASE1","title":"Thorough QT (TQT) Study of TD-4208 in Healthy Subjects","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2016-05","conditions":"Cardiac Repolarization in Healthy Subjects","enrollment":48},{"nctId":"NCT02459080","phase":"PHASE3","title":"Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":619},{"nctId":"NCT03095456","phase":"PHASE3","title":"Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2017-03-27","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)","enrollment":207},{"nctId":"NCT02578082","phase":"PHASE1","title":"Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-12","conditions":"Renal Impairment","enrollment":16},{"nctId":"NCT02581592","phase":"PHASE1","title":"Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-11","conditions":"Hepatic Impairment","enrollment":16},{"nctId":"NCT03573817","phase":"PHASE3","title":"A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2018-05-31","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":122},{"nctId":"NCT02772159","phase":"PHASE1","title":"TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":9},{"nctId":"NCT02109172","phase":"PHASE2","title":"A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":64},{"nctId":"NCT03064113","phase":"PHASE2","title":"Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2011-05","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":32},{"nctId":"NCT01704404","phase":"PHASE2","title":"7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2012-12","conditions":"COPD","enrollment":62},{"nctId":"NCT02512510","phase":"PHASE3","title":"Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":611},{"nctId":"NCT02040792","phase":"PHASE2","title":"A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-05","conditions":"COPD","enrollment":355}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["revefenacin","Revefenacin"],"phase":"phase_3","status":"active","brandName":"TD-4208","genericName":"TD-4208","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TD-4208 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}